[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"smoking-tobacco-addiction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:smoking-tobacco-addiction":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,54,80,165,189,219,259,286,311,327,356,395,416],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100053678","phase-4-varenicline-and-accelerated-transcranial-magnetic-stimulation-tms-for-quitting-nicotine-use-pilot-study-100053678",false,"NCT07145866","Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study)","Evaluation of Varenicline and Accelerated TMS for Reduction of Nicotine Use","V-TMS","Inclusion Criteria:\n\n* Age ≥ 18 and ≤65;\n* The ability to give written, informed consent;\n* Fluency in English;\n* Reported interest in quitting nicotine vaping or smoking within the next month;\n* Nicotine dependence, as defined by a score of ≥4 on the 10-question E-cigarette Dependence Inventory (ECDI) or Fagerström Test for Nicotine Dependence (FTND);\n* Smoke or vape nicotine daily for at least the past 90 days, as confirmed by self-report and timeline follow-back methods;\n* Saliva cotinine \\>30ng\u002FmL;\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding;\n* Use of smoking cessation pharmacotherapy in the past month;\n* Unwilling to abstain during the study from using smoking cessation aids other than those provided by the study;\n* Prior adverse drug reaction to varenicline;\n* Contraindication to D-Cycloserine (including allergy to D-Cycloserine, significant renal impairment or known kidney disease, pregnancy)\n* Receiving or planning to receive other TMS treatments or investigational drugs during course of participation\n* Contraindications to TMS (including seizures, metallic implants, severe existing tinnitus, etc.);\n* Contraindications to MRI (including presence of a cardiac pacemaker or pacemaker wires, metallic particles in the body, vascular clips in the head or previous neurosurgery, prosthetic heart valves, claustrophobia);\n* Inpatient psychiatric hospitalization or suicide attempts in the past six months, or recent active suicidal ideation or suicidal behavior identified at enrollment or baseline visits;\n* History of seizures and\u002For history of TBI subtypes associated with elevated seizure risk (e.g. penetrating injury and intraparenchymal hemorrhage)\n* History of unstable neurological illness or major medical illness, such as epilepsy or renal impairment, in the past six months, unless clearly resolved;\n* In the opinion of the investigators, evidence of active problem substance use severe enough to compromise ability to safely participate;\n* In the opinion of the investigators, unable to safely participate in this study and\u002For provide reliable data (e.g., claustrophobia, unable to tolerate TMS or MRI procedures, etc.).","ALL","18 Years","65 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The goal of this clinical trial is to learn if a combination of varenicline and enhanced accelerated Transcranial Magnetic Stimulation (aTMS) works to help adults quit using nicotine products. Researchers will compare varenicline + active aTMS with a single dose of D-Clycloserine to varenicline + sham (inactive) aTMS with a placebo pill to see the effect of enhanced aTMS on reaching abstinence. The main question it aims to answer is: Does receiving active enhanced aTMS + varenicline lead to higher abstinence rates and lower nicotine craving?\n\nParticipants will be asked to:\n\n* Complete 2 brain MRI scans\n* Take varenicline every day for 12 weeks\n* Quit using nicotine products at the end of the second week of varenicline\n* Complete one day of up to 20 TMS treatments\n* Take a single dose of D-Cycloserine medication on the day of TMS treatment\n* Complete 12 brief, weekly follow-up visits\n* Complete a brief daily survey each day that they take the study drug",[28,29,30,31,32],"Nicotine Dependence","Transcranial Magnetic Stimulation","Vaping","Smoking Cessation","Smoking (Tobacco) Addiction",[30,34,35,36,37,38,29,39,40],"Smoking","Nicotine","Adults","Cessation","Varenicline","TMS","D-Cycloserine","RECRUITING","2026-07-09",{"date":44,"type":45},"2026-07-13","ACTUAL",{"date":47,"type":22},"2026-08",{"date":49,"type":22},"2027-12",{"name":51,"class":52},"Massachusetts General Hospital","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":66,"conditions":67,"keywords":68,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":53},"100616095","pascal-feasibility-study-100616095","NCT07301151","PASCAL Feasibility Study","Feasibility of Using a Conversational Agent for Promoting Smoking Cessation Treatment Utilization","Inclusion Criteria:\n\n* Identify as Black or African American\n* Be at least 21 years of age\n* Meet a minimum smoking amount\n* Be willing to make a quit attempt in the next 30 days\n* Have a smartphone capable of downloading and running the study app\n* Be able to upload data from the app\n* Agree to receive text message reminders about study activities\n* Be a native English speaker\n* Reside in Minnesota.\n\nExclusion Criteria:\n\n* Medicinal nicotine use would require careful monitoring by a healthcare professional\n* Medical condition or medication used likely to significantly interfere with study outcomes or to be significantly affected by changes in smoking behavior\n* Are pregnant or breastfeeding","21 Years",{"count":63,"type":22},120,[65],"NA","The goal of this randomized study is to assess if a conversational agent (or chatbot) that the investigators have developed to help with quitting smoking is acceptable to people trying to quit smoking and to also collect initial information regarding its effectiveness.\n\nIn this study, some participants trying to quit smoking will be provided with this chatbot while other participants will not be",[31,32],[69,70],"cigarette smoking","chatbot","2026-06-23",{"date":73,"type":45},"2026-06-24",{"date":75,"type":45},"2026-06-11",{"date":77,"type":22},"2027-06-30",{"name":79,"class":52},"University of Minnesota",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":17,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":139,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":53},"100641475","qaiax-aihealth4u---ai-public-health-central-microcity-a-re-quantum-ai-agency-aka-ai-city-hall-project-upsto-app-nos-64074526-64063557-63903181-63729428-100641475","NCT07661823","QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App Nos. 64\u002F074,526, 64\u002F063,557, 63\u002F903,181, 63\u002F729,428","QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App Nos. 64\u002F074,526, 64\u002F063,557, 63\u002F903,181, 63\u002F729,428: A Quantum AI Public Health Agency That Provides Free Public Health Services to Registered and Sponsored Visitors\u002FOccupants for RDT&E Under 28 U.S. Code 1498 (Classified as a PPA Under 10 U.S. Code 129a)","QAIAx","Inclusion Criteria:\n\n* Individuals aged 17 to 99 years old.\n* Referral by a licensed health services professional (e.g., R.N., N.P., Ph.D., M.D.).\n* Referral by a non-profit organization (e.g., 501c3, university, church).\n* Referral by a public agency (e.g., case manager, social worker, parole\u002Fprobation\u002FPTS officer, judge).\n\nExclusion Criteria:\n\n\\* Individuals under 17 or over 99 years of age.",true,"17 Years","99 Years",{"count":92,"type":22},1000000,[65],"BRIEF SUMMARY\n\nA. \"What is the purpose of this study?\"\n\nThis study will test whether the \"AI City Hall Project\" (QAIAx), a quantum artificial intelligence (AI) public health agency, can provide free or low-cost behavioral and mental health services inside self-contained, dome-enclosed communities called \"Microcities\". Researchers want to see if AI-managed public administration, AI humanoid robots, holoportation of human-figures via 'holo-suites' (e.g., AI-119 Kikkeri Holo-Suit; AI-119 Vulcan QM-Ware) and advanced AI mental-health tools can lower housing and care costs, improve mental health outcomes (e.g., particular ecosystems using AI tools among persons with one or more addiction disorders), and be financially sustainable for people on fixed incomes or public assistance.\n\nB. \"What conditions does the study focus on?\"\n\nThe study focuses on adults with:\n\n* Autism spectrum disorders (Asperger's, autism, ADHD, ASD)\n* Substance use disorders (alcohol, opioids, marijuana, cocaine, MDMA\u002Fecstasy, tobacco\u002Fnicotine)\n* Psychiatric conditions (personality disorders, narcissism, gender dysphoria, eating disorders)\n* Behavioral addictions (gambling, sex addiction) and related issues (sex offence history).\n\nC. \"What does the study involve?\"\n\nEligible volunteers live in an omni AI-managed Microcity for up to 24 months. The community is housed in a geodesic dome that contains all daily necessities: housing, food, utilities, healthcare, and public services. Daily life is managed by an AI system (ISAC) and AI humanoid robots, with only occasional human oversight. Participants receive free mental-health treatment that may include AI-driven counselling, virtual-reality therapy (holo-suits), and non-invasive digital \"attitude inoculation\" protocols designed to reduce stress and addiction cravings. All participants also take AI-technology courses as a condition of enrolment. The study does not use any FDA-regulated drug, device, or biologic.\n\n\\*\\*Who can participate?\\*\\*\n\nYou may be able to join if you:\n\n* Are an adult (18 years or older)\n* Have a diagnosis of one of the listed mental-health or addiction disorders\n* Are referred by a licensed health professional (e.g., RN, NP, PhD, MD), a non-profit organisation (e.g., 501(c)(3), university, church), or a public agency (e.g., case manager, social worker, parole\u002Fprobation officer, judge)\n* Are willing to live in a closed, AI-managed community for up to one year and complete AI educational courses.\n\nParticipants who are veterans, receive public assistance (e.g., VA disability, SSDI\u002FSSI, Medicaid, Medicare), or are experiencing homelessness may be prioritised.\n\n\\*\\*Where is the study taking place?\\*\\* The study will be conducted at Microcity sites in the United States and internationally. The first administrative site is in Richmond, Virginia, USA. Additional sites are planned in partner nations, including tribal lands, military installations, and special economic zones.\n\n\\*\\*Who is sponsoring the study?\\*\\* The study is sponsored by \\*\\*Veterans Recovery Network Inc.\\*\\*, a non-profit organization, in collaboration with \\*\\*AI-119 Vulcan Project Research \\& Educational Technology Co. (PRETCO)\\*\\* and an AI legal agency. The study is conducted under U.S. federal research and development authorities (28 U.S.C. §1498; 10 U.S.C. §129a) and is part of a Cooperative Research and Development Agreement (CRADA) with U.S. Special Operations Command (USSOCOM).\n\nThis summary describes a planned clinical study. Not all details may be final. Information may change as the study progresses.",[96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,32,125,126,127,128,129,130,131,132,133,134,135,136,137,138],"Asperger's Disorder","Asperger Disorder","Autism Disorder","Autism","ADHD - Attention Deficit Disorder With Hyperactivity","ADHD","ASD","Alcohol Abuse\u002FDependence","Alcohol Addiction","Alcohol and Other Drug Use Disorders","Alcohol and Other Substance Use Prevention","Gambling Addiction","Gambling Disorder","Sex Abuse","Sex Behavior","Sex Crimes","Sex Disorder","Sex Disorders","Gender Dysphoria, Adult","Eating Behavior Disorders","Narcotic-Related Disorders","Narcotic Addiction","Narcissism","Psychiatric Disorder","Psychedelic Effects in Healthy Volunteers","Psychedelic Experiences","Psychedelic Drug Dependence","Marijuana Use Disorder","Marijuana Abuse and Dependence","Smoking Among Youth","Smoking Abstinence","Abstinence, Sex","Opiate Substitution Treatment","Opioid Abuse (Disorder)","Opioid Abuse and Addiction","Cocaine Abuse","MDMA ('Ecstasy')","Addiction Disorders","Homeless and Low Incomes People, Refugees","Homelessness","Reliability and Validity","Anger Problems","Child Abuse, Sexual",[140,141,142,143,144,145,146,147,148,149,150,151,152,153,154],"ai city hall project","ai 119","ai119","qaia","qaiax","ai wat","veterans recovery network","veterans","addiction disorder","vulcan","artificial intelligence","agi","military","sex addiction","mental health treatment","NOT_YET_RECRUITING","2026-06-16",{"date":158,"type":45},"2026-06-22",{"date":160,"type":22},"2026-08-01",{"date":162,"type":22},"2028-12-31",{"name":164,"class":52},"Veterans Recovery Network Inc.",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":88,"sex":17,"minAge":4,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":175,"briefSummary":176,"conditions":177,"keywords":180,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":187,"locationsCount":53},"100606695","designing-a-smoking-intervention-for-youth-smokers-100606695","NCT07178899","Designing a Smoking Intervention for Youth Smokers","Designing a Smoking Intervention for Youth Smokers Using Q-Methodology: A Pilot Randomized Controlled Trial","Inclusion Criteria (Phase 1):\n\n* Hong Kong citizens\n* Have ever habitually used conventional cigarettes in the past year\n* Not using cigarettes for the past 7-30 days\n* Aged 25 or below (parental consent is required for participants under 18 years old)\n* No barriers in communicating in Cantonese and reading and writing Chinese\n* Quit smoking without using cessation services\n\nInclusion Criteria (Phase 3):\n\n* Hong Kong citizens\n* Have ever habitually used conventional cigarettes in the past year\n* Received at least 4 weeks of smoking cessation service before enrolling into the study\n* abstained from tobacco use for 7 days without concurrent use of any cessation services\n* Aged 25 or below (parental consent is required for participants under 18 years old)\n* No barriers in communicating in Cantonese and reading and writing Chinese\n\nExclusion Criteria (Phase 1 \\& 3):\n\n* Have unstable physical or psychological conditions as advised by doctors or counsellors\n* Are users of illicit drugs (e.g., heroin, marijuana, ketamine, etc.)\n* Have become pregnant in the past two months\n* unable to communicate in Cantonese and read Chinese\n\nInclusion Criteria (Phase 2) (for SC counsellors) :\n\n* SC counsellors from local SC clinics under HKU Youth Quit Line, Tung Wah Group of Hospitals Integrated Center on Smoking Cessation and United Christian Nethersole Community Health Service","25 Years",{"count":174,"type":22},100,[65],"This study aims to develop a typology-based intervention delivered by smoking cessation (SC) counsellors to prevent smoking relapse in ex-smokers who recently quit. The two main research questions include (1) Can a typology-based smoking relapse prevention intervention be feasible and accepted by the smokers and SC counsellors who deliver the new intervention? (2) What is the preliminary evidence on the efficacy of the typology-based smoking relapse prevention to increase tobacco abstinence in ex-smokers who have recently quit? If the intervention shows at least a small effect size (i.e. risk ratio\\>1.3), or the intervention is feasible while modifications can potentially increase the efficacy, a future definitive RCT is warranted.",[32,178,179],"Young Adult","RCT",[31,178,179],"2026-05-29",{"date":183,"type":45},"2026-06-02",{"date":185,"type":22},"2026-06-05",{"date":77,"type":22},{"name":188,"class":52},"The University of Hong Kong",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":198,"phases":4,"briefSummary":199,"conditions":200,"keywords":205,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":53},"100635536","measuring-communal-coping-in-dual-smoking-couples-making-a-quit-attempt-100635536","NCT07553962","Measuring Communal Coping in Dual-smoking Couples Making a Quit Attempt","Communal Coping in Dual-Smoking Couples During a Quit Attempt","Inclusion Criteria:\n\n* Are over the age of 18\n* Smoke cigarettes on a daily basis\n* Smoke at least 5 cigarettes per day on average\n* Are in a committed relationship with an individual who smokes at least 5 cigarettes per day on average and is willing to participate in the study\n* Are willing to make a smoking cessation attempt at the time of enrollment into the study (applies to only one partner).",{"count":197,"type":22},250,"OBSERVATIONAL","Smoking is the leading preventable cause of death in the United States, and quitting is especially difficult for couples who both smoke. When both partners smoke, they are less likely to quit successfully and more likely to relapse compared to people whose partner does not smoke. Research suggests that the way romantic partners interact and support each other during a quit attempt can make a real difference - but researchers do not yet know enough about what kinds of support actually help.\n\nThis study examines a concept called \"communal coping,\" which refers to when partners treat a shared health challenge - like quitting smoking - as something they are facing together as a team rather than as separate individuals. Researchers believe that couples who approach quitting this way may have better outcomes.\n\nTo study this, researchers will ask both members of dual-smoking couples to complete brief daily surveys over two weeks while making a quit attempt. These surveys will track how partners support (or discourage) each other's quitting efforts on a day-to-day basis, along with cigarette use, cravings, and stress. This will help researchers understand which relationship patterns are most helpful for quitting, and identify specific targets for future couples-based smoking cessation programs.",[32,201,202,203,204,31],"Smoking ( Cigarette)","Tobacco","Tobacco Abstinence","Quitting Smoking",[206,207,208,209],"smoking cessation","tobacco","cigarette","relationships","2026-05-13",{"date":212,"type":45},"2026-05-15",{"date":214,"type":45},"2025-03-20",{"date":216,"type":22},"2026-12-01",{"name":218,"class":52},"University of Colorado, Denver",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":23,"phases":229,"briefSummary":230,"conditions":231,"keywords":237,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":4},"100638763","smoking-cessation-with-wearables-to-improve-general-oral-health-and-quality-of-life-100638763","NCT07593742","Smoking Cessation With Wearables to Improve General, Oral Health and Quality of Life","Smoking Cessation Programme in Telerehabilitation Assisted by Telemonitoring With Non-Invasive Wearable Devices for the Improvement of Oral Health, General Health and Quality of Life","Wear-Smile","Inclusion Criteria:\n\n* Subjects who smoke ≥ 5 cigarettes per day (traditional or equivalent in nicotine content in non-combustible tobacco or liquid\u002Fvape), regardless of the severity of nicotine dependence\n* Subjects ≥ 18 years of age\n* Ability and willingness to provide informed consent or presence of a legal representative who consents\n* Subjects in possession of home medical devices for measuring cardiopulmonary parameters (sphygmomanometer and pulse oximeter) (requirement applicable to participants assigned to the control group)\n\nExclusion Criteria:\n\n* Age \\\u003C 18\n* Pregnant or breastfeeding women\n* Subjects with a remote or current history of using smoking cessation methods\n* Subjects with acute dependence on alcohol or other substances of abuse other than nicotine\n* Pathologies with advanced neurocognitive degeneration\n* Unstable psychiatric conditions (subjects with active suicidal ideation, hospitalization for psychiatric reasons and\u002For changes in psychiatric medication for less than 3 months)\n* Inability or refusal to sign informed consent\n* Inability to access the integrated telemedicine platform and\u002For wearable remote monitoring devices (requirement applicable to participants assigned to the experimental group)",{"count":228,"type":22},102,[65],"Tobacco smoking remains one of the leading preventable causes of disease, disability, and premature death worldwide. According to the World Health Organization, tobacco use is responsible for more than eight million deaths each year globally, including deaths caused by direct smoking and exposure to secondhand smoke. Smoking is a major risk factor for a wide range of chronic diseases, including cardiovascular diseases, chronic respiratory diseases, several types of cancer, and numerous oral health conditions. In addition to systemic effects, tobacco use is strongly associated with oral potentially malignant disorders and oral squamous cell carcinoma, representing a significant burden for public health systems.\n\nDespite the well-documented health risks, smoking cessation remains difficult for many individuals due to the addictive properties of nicotine and the complex behavioral and psychological components associated with tobacco dependence. Multimodal smoking cessation programs that combine behavioral counseling, psychological support, and continuous monitoring have been shown to increase the likelihood of successful cessation. However, access to these programs may be limited by logistical barriers, including geographic distance, time constraints, and limited availability of specialized services.\n\nIn recent years, telemedicine and digital health technologies have emerged as promising tools to support healthcare delivery and improve access to treatment programs. Telemedicine platforms allow remote interaction between patients and healthcare professionals, facilitating communication, follow-up, and monitoring of patients over time. Additionally, wearable devices and remote monitoring systems enable the collection of physiological and behavioral data outside traditional clinical settings, providing clinicians with valuable information to support personalized interventions.\n\nThe aim of this study is to evaluate the effectiveness and feasibility of a smoking cessation program delivered through a telerehabilitation model supported by an integrated telemedicine platform and wearable remote monitoring devices. The program is designed to support individuals who smoke tobacco products, including both combustible tobacco and alternative nicotine-containing products, by providing behavioral and psychological interventions combined with continuous remote monitoring.\n\nParticipants enrolled in the study will be assigned to one of two groups. The intervention group will participate in a telerehabilitation program delivered through a dedicated telemedicine platform. This program will include structured behavioral and psychological treatment sessions aimed at supporting smoking cessation, along with remote monitoring through non-invasive wearable devices that allow healthcare professionals to track selected physiological parameters and patient engagement during the treatment process.\n\nThe control group will receive the same multimodal behavioral and psychological treatment program but delivered through conventional rehabilitation methods without the use of telemedicine technologies or wearable monitoring devices.\n\nBy comparing these two approaches, the study aims to explore whether the integration of telemedicine and wearable technologies into smoking cessation programs may improve patient engagement, facilitate monitoring, and potentially enhance the effectiveness of behavioral interventions aimed at reducing tobacco use. The findings of this study may contribute to the development of innovative digital health strategies for smoking cessation and provide evidence to support the integration of telemedicine into addiction treatment and preventive healthcare programs.",[201,32,232,31,233,234,235,236,126],"Smoking Behaviors","Smoking Dependence","Smoking Addiction","Smoking Cessation Intervention","Smoking E-cigarette",[34,238,239,202,240,241,242,243,244,245,246,247,248,249],"Smoking cessation","Smoking addiction","Wearable device","Telerehabilitation","Oral Health","Periodontal Health","General Health","Quality of life","Periodontal disease","E-cigarette","Heat not burn tobacco","Smoking abstinence","2026-05-11",{"date":252,"type":45},"2026-05-18",{"date":254,"type":22},"2026-06-01",{"date":256,"type":22},"2027-11-01",{"name":258,"class":52},"University of Salerno",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":88,"sex":17,"minAge":18,"maxAge":266,"enrollmentInfo":267,"targetDuration":4,"studyType":23,"phases":269,"briefSummary":270,"conditions":271,"keywords":274,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":285},"100588724","act-lung-health-intervention-phase-two-100588724","NCT06945120","ACT Lung Health Intervention: Phase Two","Efficacy of an Asian Culture-tailored Lung Health (ACT) Intervention on Lung Cancer Screening and Smoking Cessation in Asian Americans","Inclusion Criteria:\n\n* Self-identify as either Chinese or Korean\n* Speak either Korean, Mandarin, or English\n* Are 18 years of age or older\n* Are current smokers (i.e., have smoked at least 100 traditional cigarettes ever and have smoked at least one traditional cigarette within the prior 30 days)\n* Will live in the United States for the next 12 months\n\nExclusion Criteria:\n\n* Hospitalization due to a serious mental illness (e.g., psychotic disorders) during the prior 6 months.\n* We will not include any of the following special populations:\n\n  * Adults unable to consent.\n  * Adults younger than 50 or older than 80 years\n  * Individuals who are not yet adults (infants, children, teenagers)\n  * Pregnant women\n  * Prisoners","100 Years",{"count":268,"type":22},50,[65],"This study aims to test a counseling and educational program designed to improve lung health through smoking cessation for Chinese and Korean American smokers at high risk for lung cancer.",[31,232,272,273,32],"Smoking, Tobacco","Smoking, Cigarette",[31,275,32,273,272,232],"Lung Cancer Screening","2026-03-11",{"date":278,"type":45},"2026-03-13",{"date":280,"type":45},"2025-11-04",{"date":282,"type":22},"2026-12-31",{"name":284,"class":52},"Dana-Farber Cancer Institute",2,{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":88,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":23,"phases":296,"briefSummary":297,"conditions":298,"keywords":300,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":53},"100599153","oklahoma-study-of-native-american-pain-risk-iv-smoking-cessation-and-pain-100599153","NCT07080788","Oklahoma Study of Native American Pain Risk IV: Smoking Cessation and Pain","Can Smoking Cessation Improve Physiological Markers of Chronic Pain Risk in Native American Smokers?: A Pilot Feasibility Study","OK-SNAPIV","Inclusion Criteria:\n\n* Self-identify as Native American\u002FAmerican Indian\n* Currently daily smoker\n* Own a smartphone with a data plan\n* Ability to speak and read English\n\nExclusion Criteria:\n\n* \\>18 years of age\n* Currently pregnant\n* Self-reported history of heart disease or heart attack\n* Angina, arrhythmias, hypertension, heart disease\n* Current chronic pain\n* Pepper allergy\n* Inability to speak English\n* Current psychosis (assessed by Psychosis Screening Questionnaire)\n* Serious cognitive impairment (assessed by \\\u003C20 score on the Montreal Cognitive Assessment \\[MoCA\\])",{"count":295,"type":22},150,[65],"The goal of this pilot study is to assess whether 4-weeks of verified smoking abstinence following financial incentive treatment for smoking cessation improves physiological markers of chronic pain risk in adult Native American smokers.\n\nThe main aims to answer are:\n\n1. Determine study feasibility.\n2. Obtain effect sizes for changes in pain amplification and pain inhibition in abstinent vs non-abstinent Native Americans.\n3. Obtain effect sizes for variables in the conceptual model of the Native American smoking-pain relationship.",[235,299,32],"Pain",[238,301],"Quantitative sensory testing","2026-02-26",{"date":304,"type":45},"2026-03-02",{"date":306,"type":45},"2025-09-01",{"date":308,"type":22},"2028-06",{"name":310,"class":52},"University of Oklahoma",{"id":312,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":314,"targetDuration":4,"studyType":23,"phases":315,"briefSummary":316,"conditions":317,"keywords":318,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":53},"100604157","Inclusion Criteria:\n\n* Age ≥ 18 and ≤65;\n* The ability to give written, informed consent;\n* Fluency in English;\n* Reported interest in quitting nicotine vaping or smoking within the next month;\n* Nicotine dependence, as defined by a score of ≥4 on the 10-question E-cigarette Dependence Inventory (ECDI) or Fagerström Test for Nicotine Dependence (FTND);\n* Smoke or vape nicotine daily for at least the past 90 days, as confirmed by self-report and timeline follow-back methods;\n* Saliva cotinine \\>30ng\u002FmL;\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding;\n* Use of smoking cessation pharmacotherapy in the past month;\n* Unwilling to abstain during the study from using smoking cessation aids other than those provided by the study;\n* Prior adverse drug reaction to varenicline;\n* Receiving or planning to receive other TMS treatments or investigational drugs during course of participation\n* Contraindications to TMS (including seizures, metallic implants, severe existing tinnitus, etc.);\n* Contraindications to MRI (including presence of a cardiac pacemaker or pacemaker wires, metallic particles in the body, vascular clips in the head or previous neurosurgery, prosthetic heart valves, claustrophobia);\n* Inpatient psychiatric hospitalization or suicide attempts in the past six months, or recent active suicidal ideation or suicidal behavior identified at enrollment or baseline visits;\n* History of seizures and\u002For history of TBI subtypes associated with elevated seizure risk (e.g. penetrating injury and intraparenchymal hemorrhage)\n* History of unstable neurological illness or major medical illness, such as epilepsy or renal impairment, in the past six months, unless clearly resolved;\n* In the opinion of the investigators, evidence of active problem substance use severe enough to compromise ability to safely participate;\n* In the opinion of the investigators, unable to safely participate in this study and\u002For provide reliable data (e.g., claustrophobia, unable to tolerate TMS or MRI procedures, etc.).",{"count":21,"type":22},[25],"The goal of this clinical trial is to learn if a combination of varenicline and accelerated Transcranial Magnetic Stimulation (aTMS) works to help adults quit using nicotine products. Researchers will compare varenicline + active aTMS to varenicline + sham (inactive) aTMS to see the effect of aTMS on reaching abstinence. The main question it aims to answer is: Does receiving active aTMS + varenicline lead to higher abstinence rates and lower nicotine craving?\n\nParticipants will be asked to:\n\n* Complete 2 brain MRI scans\n* Take varenicline every day for 12 weeks\n* Quit using nicotine products at the end of the second week of varenicline\n* Complete 5 consecutive days (Monday-Friday, uninterrupted) of TMS treatments\n* Complete 12 brief, weekly follow-up visits\n* Complete a brief daily survey each day that they take the study drug",[28,29,30,31,32],[30,34,35,36,37,38,29,39],"2026-01-14",{"date":321,"type":45},"2026-01-16",{"date":323,"type":22},"2026-03-15",{"date":325,"type":22},"2027-12-01",{"name":51,"class":52},{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":23,"phases":336,"briefSummary":338,"conditions":339,"keywords":343,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":352,"leadSponsor":354,"locationsCount":53},"100606097","phase-2-smoking-cessation-trial-in-recurrent-acute-pancreatitis-and-chronic-pancreatitis-100606097","NCT07171112","Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis","Smoking Cessation Treatment Escalation Among Patients With Recurrent Acute Pancreatitis and Chronic Pancreatitis","Inclusion Criteria\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged 18 or older\n* Diagnosed with either recurrent acute pancreatitis or chronic pancreatitis as defined by the American Pancreatic Association:\n\n  o Chronic Pancreatitis (any of the following): i. Moderate\u002Fmarked pancreas imaging morphology (i.e. ductal and parenchymal abnormalities ii. Pancreatic calcifications iii. Histologic confirmation\n\n  o Recurrent Acute Pancreatitis: i. Two or more documented attacks of acute pancreatitis, separated by 3 months from one another, defined by at least 2 of the following 3:\n  1. amylase or lipase values, or both, that are greater than 3 times the upper limit of normal values\n  2. characteristic cross-sectional imaging\n  3. typically upper abdominal pain according to the revised Atlanta classification\n* Currently smoking ≥ 5 cigarettes\u002Fday\n* Explicitly express a desire to quit within 30 days\n* Ability to take oral medication and be willing to adhere to the study intervention regimen\n* Willing and able to comply with trial protocol and follow-up\n\nExclusion Criteria\n\n* Age \\\u003C 18 years\n* Ongoing acute pancreatitis or prior episode of pancreatitis in previous 30 days\n* No desire to quit smoking\n* Currently undergoing smoking cessation intervention (i.e. nicotine replacement therapy, varenicline, counseling, bupropion).\n* Known allergic reactions to varenicline or bupropion SR\n* History of seizures\n* History of an eating disorder (anorexia or bulimia)\n* Closed head trauma with any loss of consciousness or amnesia in the last 5 year\n* Ever history of closed head trauma with \\> 30 minutes of loss of consciousness or amnesia or resulting in skull fracture or subdural hematoma\u002Fbrain contusion\n* Ever history of alcohol withdrawal\n* Ever history of chronic kidney disease (creatine clearance \\\u003C 30 mL\u002Fminute)\n* Liver impairment (i.e. history of cirrhosis) with aminotransferase elevation ≥ 2 times the upper limit of normal and\u002For alkaline phosphatase elevation ≥ 2 times the upper limit of normal.\n* History of bipolar disorder or psychosis\n* Ongoing or recent use (prior 14 days) of any monoamine oxidase inhibitors (isocarboxazid, phenelzine, tranylcypromine, selegiline).\n* Regular use of potent CYP2B6 inhibitors (i.e. clopidogrel, ticlopidine)\n* Regular use of CYP2D6 substrates with narrow therapeutic indices (e.g. flecainide, propafenone, tricyclic antidepressants such as nortriptyline, thioridazine, vinblastine)\n* History of acute angle closure glaucoma\n* Meet criteria for depression as assessed by the Center for Epidemiologic Studies - Depression (CES-D) with a score of 16 or higher.\n* Psychiatric hospitalization within 1 year of screening\n* Participants who have a score of 3 or higher on the Columbus-Suicide Severity Rating Scale (C-SSRS) at enrollment or during any of the study assessments will be excluded\n* Unable to provide consent for self Incarcerated\n* Pregnant females. All female patients of childbearing potential must have a negative pregnancy test and must agree to use highly effective (failure rate \\\u003C1%) contraception during participation in the study.",{"count":335,"type":22},45,[337],"PHASE2","The purpose of this research is to assess the effectiveness of two treatment strategies for smoking cessation in patients with acute recurrent pancreatitis or chronic pancreatitis who smoke cigarettes. All participants will receive varenicline, a commonly used medication that helps people stop smoking, at its standard dose. For those who are unable to stop smoking after 6 weeks of treatment, they will be randomly selected to either 1) increase their dose of varenicline, 2) combine varenicline with bupropion (another medication that helps with smoking cessation) or continue on the standard dose of varenicline. At the end of 12 weeks of treatment, participants will be asked if they have stopped smoking with confirmation done by measuring carbon monoxide levels in their breath.",[340,341,342,32],"Pancreatitis, Chronic","Pancreatitis, Acute","Recurrent Acute Pancreatitis",[238,344,345,346,347],"chronic pancreatitis","recurrent acute pancreatitis","varenicline","bupropion","2025-11-06",{"date":350,"type":45},"2025-11-10",{"date":348,"type":45},{"date":353,"type":22},"2028-10-01",{"name":355,"class":52},"Mayo Clinic",{"id":357,"slug":358,"hasResults":11,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":4,"eligibilityCriteria":362,"healthyVolunteers":88,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":363,"targetDuration":4,"studyType":23,"phases":365,"briefSummary":366,"conditions":367,"keywords":372,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":394},"100569396","a-study-evaluating-the-use-of-an-indoor-air-quality-monitor-to-promote-a-smoke-free-home-100569396","NCT06693700","A Study Evaluating the Use of an Indoor Air Quality Monitor to Promote a Smoke-free Home","Freedom to Breathe: Pilot Study Towards Achieving Environmental Justice for Cancer Patients and Their Families","Inclusion Criteria:\n\n* Adult (aged \\>18 years) MSK patients as per the EHR\n* Has been referred and enrolled in the MSK TTP and completed the initial counseling session as per the TTP clinical database\n* Reports current (within the past 30 days) tobacco use (i.e., cigarettes and\u002For any other tobacco products) as per the TTP Intake form\n* Must be English-speaking in the EHR\n* Must be reachable by phone as per self-report\n* Must have Wi-Fi available at home as per self-report\n\nExclusion Criteria:\n\n* Patient reports that no smoking is allowed, by them or anyone else, in the home as per the TTP intake form and\u002For per self-report",{"count":364,"type":22},10,[65],"The purpose of this study is to evaluate how using an indoor air quality monitor can promote a smoke-free home for cancer patients who are enrolled in MSK's Tobacco Treatment Program.",[34,31,368,369,232,272,273,32,370,371],"Smoking Reduction","Smoking Habit","Tobacco Use","Tobacco Smoking",[373,206,374,375,376,377,378,379,380,381,382,383,384,385],"smoking","smoking reduction","smoking habit","smoking behaviors","smoking, tobacco","smoking, cigarette","smoking (tobacco) addiction","tobacco use","tobacco smoking","air quality","indoor air quality monitoring devices","24-260","Memorial Sloan Kettering Cancer Center","2025-10-21",{"date":388,"type":45},"2025-10-22",{"date":390,"type":45},"2024-11-14",{"date":392,"type":22},"2027-11-14",{"name":385,"class":52},8,{"id":396,"slug":397,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":88,"sex":17,"minAge":61,"maxAge":402,"enrollmentInfo":403,"targetDuration":4,"studyType":23,"phases":404,"briefSummary":405,"conditions":406,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":53},"100564557","phase-4-addiction-potential-of-very-low-nicotine-filtered-little-cigars-100564557","NCT06630728","Addiction Potential of Very Low Nicotine Filtered Little Cigars","LOWFLC","Inclusion Criteria:\n\n* Smokers: 1) self-reported regular current filtered little cigars, cigarillos, little cigars, or small cigars use for the past 3 months; regular use will be defined as \\>=8 cigars smoked per month based on data showing median cigarillo use is 7.5 times per month and median FLC use is 14 times per month 59. We will attempt to bring in heavier users if feasible during recruitment; or 2) Cigarette smokers (\\>=8d\u002Fmonth for at least 3 months) with either (i) co-use of filtered little cigars, cigarillos, little cigars, or small cigars (at least once in their lifetime) or (ii) answering \"yes\" to the question \"If all cigarettes were taken off the market, would you consider switching to filtered little cigars?\"\n* willing to abstain from all tobacco and nicotine for at least 12 hours prior to lab sessions\n* Willing to bring their own, preferred brand little cigars\u002F small cigars\u002F cigarillos\u002F filtered little cigars to smoke in the lab on the first study visit\n* capable of and willing to provide written informed consent\n* read and speak in English.\n\nExclusion Criteria:\n\n* Self-reported significant current lung disease (e.g. asthma, COPD, cystic fibrosis, pulmonary fibrosis); exercise-induced asthma, seasonal allergies for which a patient takes inhalers are allowed\n* History of diagnosis or treatment for lung cancer\n* Self-reported serious or uncontrolled kidney disease, liver disease, metabolic disease (thyroid, diabetes)\n* History of cardiac event or distress within the past 3 months\n* Unstable or significant psychiatric conditions (past and stable conditions will be allowed)\n* Substance use disorders besides nicotine addiction\n* Regular use of other tobacco products besides cigarettes such as snuff, chewing tobacco, snus, e-cigarettes \\>10d per month\n* Exclusive large or premium cigar users\n* Use of blunts every time or most of the time\n* Regular use of cannabis \\>10d per month\n* Planning to quit in next 30 days or currently trying to quit or quit attempt in past 30 days\n* Pregnant, delivery in past 12 weeks, breastfeeding, or planning to get pregnant\n* Inability to perform tests or follow instructions during testing","75 Years",{"count":268,"type":22},[25],"The goal of this clinical trial is to learn how reducing the nicotine content in filtered little cigars can affect the the use of these cigars and lung health in current adult filtered little cigar users. The main question\\[s\\] it aims to answer are:\n\nAre puffing behaviors, appeal\u002Fsatisfaction, craving suppression, pharmacokinetic effects, and demand similar between the regular cigars smoked by participants, normal nicotine study cigars and very low nicotine study cigars? Are health effects and toxicant exposure similar between the regular cigars smoked by participants, normal nicotine study cigars and very low nicotine study cigars?\n\nParticipants will attend three study visits at OSU. Each visit would last up to 4 hours. During visits, they will\n\n* fill several surveys\n* provide blood samples\n* perform breathing tests\n* complete smoking sessions using either their own cigars or the study cigars.",[32],"2025-10-15",{"date":409,"type":45},"2025-10-16",{"date":411,"type":45},"2025-02-13",{"date":413,"type":22},"2028-01",{"name":415,"class":52},"Ohio State University Comprehensive Cancer Center",{"id":417,"slug":418,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":423,"targetDuration":4,"studyType":23,"phases":425,"briefSummary":426,"conditions":427,"keywords":428,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":434,"leadSponsor":436,"locationsCount":53},"100607245","impact-of-exercise-associated-with-cognitive-behavioral-therapy-in-smokers-100607245","NCT07186049","Impact of Exercise Associated With Cognitive-behavioral Therapy in Smokers","Impact of Exercise Associated With Cognitive-behavioral Therapy in Smokers: a Randomized Clinical Trial","Inclusion criteria:\n\n* Participants 18 years of age or older;\n* Clinical diagnosis of active smoking of combustible cigarettes;\n\nExclusion criteria:\n\n* Unstable heart disease or severe orthopedic problems;\n* Cognitive disorders that may interfere with understanding and participation in behavioral interventions;",{"count":424,"type":22},66,[65],"Smoking remains one of the leading causes of global morbidity and mortality, responsible for more than 8 million deaths annually, according to data from the World Health Organization. In addition to its physical effects, such as cancer, cardiovascular, and respiratory diseases, tobacco use also negatively impacts mental health and quality of life (QoL). Despite public health measures, its prevalence remains high, especially among vulnerable groups, requiring integrated approaches that address both the physiological and psychological aspects of addiction.\n\nThis study aims to evaluate the effects of combining physical exercise and cognitive behavioral therapy (CBT) on smoking cessation. Specifically, it seeks to assess the effectiveness of a structured exercise program in promoting abstinence, improving physical and mental health, and reducing cigarette consumption, as well as analyzing the impacts on fatigue, lung function, exercise capacity, and quality of life of participants over a 12-week intervention.\n\nMethodologically, a randomized clinical trial will be conducted with 66 smokers recruited from the Piquet Carneiro Polyclinic of the Rio de Janeiro State University. Participants will be randomly assigned to three groups: CBT alone, CBT combined with structured exercises, and a control group with general health counseling. Assessments will include spirometry, impulse oscillometry, the FACIT-Fatigue scale, the Fagerström test, a cardiopulmonary exercise test, and the SF-36 questionnaire, administered at three time points: baseline, 6 weeks, and 12 weeks.\n\nThe combination of exercise and CBT is expected to significantly increase abstinence rates, promoting improvements in physical and mental health parameters, reduced cigarette consumption, increased exercise capacity, improved lung function, and decreased fatigue. Furthermore, a reduction in anxiety and depression levels is expected, reflecting the effectiveness of behavioral strategies in modulating the psychological factors associated with smoking.\n\nThis study is highly relevant to Rehabilitation Sciences, as it proposes an integrated intervention that can support the development of more effective and holistic public health programs aligned with national targets and the Sustainable Development Goals. By exploring the interface between physical activity, mental health, and smoking cessation, it contributes to the training of more qualified health professionals and the advancement of patient-centered rehabilitation strategies, promoting sustainable benefits to public health.",[32],[429],"Smoking; Physical exercise; Cognitive-behavioral therapy","2025-09-24",{"date":432,"type":45},"2025-09-30",{"date":388,"type":22},{"date":435,"type":22},"2028-06-30",{"name":437,"class":52},"Agnaldo José Lopes"]